quantisnow
FeedTopReportsPricing
⌘K
Live feed
08:45:00·2045d
PRRelease
Novavax Inc. logo
NanoViricides Inc. logo
Gilead Sciences Inc. logo
+2

Nanomedicine Seen As A Promising Approach For Diagnosis and Treatment Against COVID

NVAX· Novavax Inc.NNVC· NanoViricides Inc.GILD· Gilead Sciences Inc.IMMU· Immunomedics, Inc.INO· Inovio Pharmaceuticals Inc.
Health Care
Full content unavailable. See the original source below.
Original source

Companies

  • NVAX
    Novavax Inc.
    Health Care
  • NNVC
    NanoViricides Inc.
    Health Care
  • GILD
    Gilead Sciences Inc.
    Health Care
  • IMMU
    Immunomedics, Inc.
    Health Care
  • INO
    Inovio Pharmaceuticals Inc.
    Health Care

Recent analyst ratings

  • Mar 10GILDUpdateJefferies$180.00
  • Feb 20GILDUpdateBarclays$155.00
  • Feb 11GILDUpdateNeedham$170.00
  • Jan 7GILDUpdateUBS$145.00
  • Dec 16NNVCUpdateAlliance Global Partners-
  • Nov 24GILDUpdateTruist$140.00

Related

  • PR1d
    Gilead Sciences to Release First Quarter 2026 Financial Results on Thursday, May 7, 2026
  • NEWS2d
    Deadly Measles Cases Accentuate the Need for a Treatment - NV-387 is Here to Help Patients and Control Spread, Says NanoViricides
  • PR6d
    Gilead Receives All Required Regulatory Approvals for the Acquisition of Arcellx and Extends Tender Offer
  • INSIDER7d
    SEC Form 4 filed by Dickinson Andrew D
  • INSIDER7d
    SEC Form 4 filed by Mercier Johanna
  • INSIDER7d
    SEC Form 4 filed by Walker Robert Edward
  • INSIDER7d
    SEC Form 3 filed by new insider Walker Robert Edward
  • PR9d
    PEPFAR and The Global Fund Make Additional Investment in Gilead's Lenacapavir for HIV Prevention to Further Expand Access
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022